Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
May 03 2022 - 8:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
company focused on treatments for gastrointestinal (GI) diseases,
today announced that the Company is scheduled to release its first
quarter 2022 financial results on Tuesday, May 10, 2022, after the
market closes.
Management will host a conference call on Tuesday May 10, 2022,
at 4:30 p.m. ET to discuss the results. The dial-in numbers for the
conference call are (800) 891-3840 for domestic callers and (785)
424-1249 for international callers. Please reference participant
code EVOKQ122 when prompted.
In addition, a telephonic replay of the call will be available
until May 13, 2022. The replay dial-in numbers are (800) 839-6910
for domestic callers and (402) 220-6058 for international
callers.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on
the development of drugs to treat GI disorders and diseases. The
company developed, commercialized and markets GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults.
Diabetic gastroparesis is a GI disorder affecting millions of
patients worldwide, in which the stomach takes too long to empty
its contents resulting in serious GI symptoms as well as other
systemic complications. The gastric delay caused by gastroparesis
can compromise absorption of orally administered medications. Prior
to FDA approval to commercially market GIMOTI, metoclopramide was
only available in oral and injectable formulations and remains the
only drug currently approved in the United States to
treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow GIMOTI on
Facebook: https://www.facebook.com/GIMOTI-metoclopramide-nasal-spray-104672345100289
Follow Evoke Pharma on
Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724
Follow Evoke Pharma on
LinkedIn: https://www.linkedin.com/company/evoke-pharma/
Safe Harbor Statement
Evoke cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negatives of these
terms or other similar expressions. These statements are based on
the company’s current beliefs and expectations. These
forward-looking statements include statements regarding: the size
of the gastroparesis market and the potential of GIMOTI to treat
patients with diabetic gastroparesis. The inclusion of
forward-looking statements should not be regarded as a
representation by Evoke that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Evoke’s
business, including, without limitation: Evoke’s and EVERSANA’s
ability to successfully drive market demand for GIMOTI; Evoke’s
ability to obtain additional financing as needed to support its
operations, including through the EVERSANA line of credit which is
subject to certain customary conditions; the COVID-19 pandemic may
disrupt Evoke’s and EVERSANA’s business operations impairing the
ability to commercialize GIMOTI and Evoke’s ability to generate any
product revenue; Evoke’s dependence on third parties for the
manufacture of GIMOTI; Evoke is entirely dependent on the success
of GIMOTI; inadequate efficacy or unexpected adverse side effects
relating to GIMOTI that could result in recalls or product
liability claims; Evoke’s ability to obtain and maintain
intellectual property protection for GIMOTI; and other risks
detailed in Evoke’s prior press releases and in the periodic
reports it files with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Evoke undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor Contact:Daniel Kontoh-BoatengDKB
Partnersdboateng@dkbpartners.netTel: 862-213-1398
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Apr 2023 to Apr 2024